<DOC>
	<DOCNO>NCT00729742</DOCNO>
	<brief_summary>This study use image look tumor response erlotinib ( Part I ) combination erlotinib dalotuzumab ( Part II ) .</brief_summary>
	<brief_title>Phase I Imaging Study Evaluating Dalotuzumab ( MK0646 ) Combination With Erlotinib Patients With Non-Small Cell Lung Cancer ( MK-0646-008 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patient locally advance metastatic stage IIIB/IV Nonsmall cell lung cancer Patient measurable disease Patient accessible tumor consent undergo tumor biopsy [ Part II ] Patient 18 year age old Patient performance status 02 ECOG scale Women childbearing potential negative pregnancy test Patients Part I must : 1. female nonsmoker nonsquamous histology one two prior systemic chemotherapy 2. document EGFR mutation EGFR gene amplification , regardless demographic clinical characteristic , two prior systemic chemotherapy . Patients Part II must one two chemotherapy regimen recurrent metastatic disease Patient chemotherapy within 2 week biological therapy ( e.g . bevacizumab ) within 4 week Patient recover adverse event previous therapy within 4 week Patient receive EGFRTKI inhibitor/antiEGFR mAb therapy Patient receive IGF1RTKI inhibitor/antiIGF1R mAB therapy Patient untreated brain metastasis Patient radiotherapy field affect chest abdomen , thoracic surgery within 3 month prior enter study Patient take part another clinical study Patient abuse drug alcohol Patient pregnant breastfeeding Subject HIV positive Patient active hepatitis Patient use growth hormone growth hormone inhibitor Patient poorly control diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>